bioRxiv Science⌕ Search

Biology subjects

Pardo Calvo, M.

Publications and source records attributed to Pardo Calvo, M..

2 recordsLinked to original sources

High resolution interaction surface mapping by PRISMA reveals novel ARID1A interactions

The SWI/SNF chromatin remodelling complex controls proliferation and cell fate determination by regulating chromatin accessibility at promoters and enhancers, thereby modulating programs of gene expression, and has roles in DNA damage response, replication, splicing, and translation, and cell plasticity. The cBAF-exclusive subunit ARID1A acts as scaffold for the assembly of cBAF SWI/SNF complexes through its C-terminal globular domain and is the most frequently mutated SWI/SNF subunit in cancer. More than half of the ARID1A protein sequence contains regions of intrinsic disorder which are important for protein interactions, often mediated by short linear motifs. However, these interactions are notoriously difficult to study. Whilst hundreds of ARID1A interactions have been reported in the literature, their molecular basis remains obscure, and only a few have been explored functionally or mapped at an interface level. Here, we use a PRotein Interaction Screen on a peptide MAtrix (PRISMA) combined with quantitative mass spectrometry to identify novel ARID1A interactions and map amino acid residues and motifs that mediate interactions at high sequence resolution. The ARID1A PRISMA assay recapitulates binding of BAF subunits to ARID1A and detects the previously described binding of YAP1 transcriptional coactivator to a PPXY motif. Our PRISMA data reveals binding sites for transcriptional repressor SIN3A and identifies TOX4, CDK2 and CCNA2 as novel interactors. Mutation of a cell cycle-dependent CDK2 phosphorylation site in ARID1A leads to altered gene expression of microtubule factors and defects in cell proliferation. Our work underscores the utility of PRISMA to uncover weak or low abundance interactions that are not detectable by traditional affinity purification strategies. Together, our results characterise novel interactors and a new mode of regulation of ARID1A, and provide a useful resource to further explore mechanistic aspects of ARID1A function.

biochemistry↗

The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatin

Summary paragraphPoly-(ADP-ribose) polymerase inhibitors (PARPi) elicit anti-tumour activity in homologous recombination defective cancers by promoting cytotoxic, chromatin-bound, "trapped" PARP1. How cells process trapped PARP1 remains unclear. By exploiting wild-type or trapping-resistant PARP1 transgenes combined with either a rapid immunoprecipitation mass-spectrometry of endogenous proteins (RIME)-based approach, or PARP1 Apex2-proximity labelling linked to mass-spectrometry, we generated proteomic profiles of trapped and non-trapped PARP1 complexes. This combined approach identified an interaction between trapped PARP1 and the ubiquitin-regulated p97 ATPase (aka VCP). Subsequent experiments demonstrated that upon trapping, PARP1 is SUMOylated by the SUMO-ligase PIAS4 and subsequently ubiquitinated by the SUMO-targeted E3-ubiquitin ligase, RNF4, events that promote p97 recruitment and p97 ATPase-mediated removal of trapped-PARP1 from chromatin. Consistent with this, small molecule p97 complex inhibitors, including a metabolite of the clinically-used drug disulfiram (CuET) that acts as a p97 sequestration agent, prolong PARP1 trapping and thus enhance PARPi-induced cytotoxicity in homologous recombination-defective tumour cells and patient-derived tumour organoids. Taken together, these results suggest that p97 ATPase plays a key role in the processing of trapped PARP1 from chromatin and the response of homologous recombination defective tumour cells to PARPi.

molecular biology↗